Market Size of Global Point-of-Care Molecular Diagnostics Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 3.67 Billion |
Market Size (2029) | USD 5.57 Billion |
CAGR (2024 - 2029) | 8.77 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Point of Care Molecular Diagnostics Market Analysis
The Global Point-of-Care Molecular Diagnostics Market size is estimated at USD 3.67 billion in 2024, and is expected to reach USD 5.57 billion by 2029, growing at a CAGR of 8.77% during the forecast period (2024-2029).
Molecular diagnostics has been the front runner in the world's response to the COVID-19 pandemic. For instance, in May 2021, a research paper published in the US National Library of Medicine titled 'Point-of-Care PCR Assays for COVID-19 Detection' stated that reverse transcriptase-polymerase chain reaction (RT-PCR) and the quantitative variant (qRT-PCR) have been the gold standard for COVID-19 diagnosis. However, molecular diagnostic technologies have some limitations. For instance, in November 2020, a research paper published in the US National Library of Medicine titled 'Molecular diagnostic technologies for COVID-19: Limitations and challenges' stated that modern molecular diagnostics are not intended for point-of-care diagnosis of COVID-19 but provide a core diagnostic solution to conduct large numbers of tests in a reasonable timeframe. Therefore, an accurate diagnosis of the disease is crucial to curb its spread. Such research studies provide better insight into the applications and limitations of molecular diagnostic technologies. Product launches are another factor in the growth of the market. For instance, in November 2021, Sense Biodetection received USD 65 million in funding to support the anticipated US and European commercial launch of Sense's COVID-19 Test on the company's Veros instrument-free molecular platform.
Point-of-care (POC) molecular testing enables physicians to improve the standard of care by combining quick diagnosis with treatment decisions during the patient's first visit. In past decades, the prevalence of infectious diseases and chronic illnesses like cancer increased. The surging prevalence of chronic illnesses, such as cancer and infectious diseases, is expected to drive the market's growth. For instance, according to the Department of Health & Human Services 2020, about 38 million people were affected by HIV/AIDS in 2019. Therefore, people with HIV are creating a need for point-of-care molecular diagnostics devices for remote locations. As per the March 2020 report of the European Centre for Disease Control and Prevention, 52,862 new tuberculosis cases were reported in 2018 in 30 EU and European Economic Area (EU/EEA) countries, with a notification rate of 10.2 per 100,000 people in the EU/EEA. Out of the total diagnosed cases in 2018, 36,047 cases of tuberculosis were confirmed by culture or smear and nucleic acid amplification test (polymerase chain reaction test). This prevalence has led to increased demand for novel diagnostic methods, further leading to progress in technological advancements and pharmacogenomics. This factor has also increased the demand for POC testing. Such factors are contributing to the market's growth.
However, uncertain reimbursement scenarios have dissuaded many manufacturers from entering the market. A lack of high-complexity test centers to use POC molecular testing is also hindering the market's growth.
Point of Care Molecular Diagnostics Industry Segmentation
Point-of-care molecular tests check for certain changes in a gene or chromosome that may cause or affect the chance of developing a specific disease or disorder, such as cancer, at or near the point-of-care, i.e., at the time and place of the patient care. The point-of-care molecular diagnostics market is segmented by application (infectious diseases, oncology, hematology, prenatal testing, endocrinology, and other applications), technology (PCR, genetic sequencing, hybridization, and microarray), end user (hospitals, homecare, and other end users), geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
By Application | |
Infectious Diseases | |
Oncology | |
Hematology | |
Prenatal Testing | |
Endocrinology | |
Other Applications |
By Technology | |
PCR | |
Genetic Sequencing | |
Hybridization | |
Microarray |
By End User | |
Hospitals | |
Homecare | |
Other End Users |
By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Point-of-Care Molecular Diagnostics Market Size Summary
The point-of-care molecular diagnostics market is poised for significant growth, driven by the increasing prevalence of infectious diseases and chronic illnesses such as cancer. This market segment has gained prominence due to its critical role in rapid diagnosis and treatment decision-making, particularly highlighted during the COVID-19 pandemic. The demand for quick and accurate diagnostic solutions is further fueled by the rising incidence of diseases like HIV/AIDS and tuberculosis, which necessitate innovative diagnostic methods. Technological advancements and product launches, such as those by Sense Biodetection and Agilent Technologies, are enhancing the capabilities and reach of point-of-care testing, thereby expanding market opportunities. However, challenges such as uncertain reimbursement scenarios and a lack of high-complexity test centers continue to pose hurdles to market expansion.
The market landscape is characterized by a consolidation of global key players, including Abbott Laboratories, Bayer AG, and Hoffmann-La Roche Ltd, who dominate the development and distribution of point-of-care molecular diagnostic tests. These companies benefit from substantial research funding and established distribution networks, solidifying their market positions. The North American region, with its well-structured healthcare system and supportive R&D policies, remains a focal point for market growth, attracting global players and facilitating numerous product launches. Meanwhile, the Asia-Pacific region is witnessing the emergence of smaller players, contributing to market diversification. Strategic agreements and investments, such as those by Sense Biodetection and FIND, are further propelling the development and deployment of affordable diagnostic platforms, enhancing the market's growth trajectory.
Global Point-of-Care Molecular Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Infectious Diseases and Cancer
-
1.2.2 Rising Demand for Point-of-care Diagnostics
-
1.2.3 Recent Advancements in Technology and Pharmacogenomics
-
-
1.3 Market Restraints
-
1.3.1 Uncertain Reimbursement Scenario
-
1.3.2 Need for High-complexity Testing Centers
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Application
-
2.1.1 Infectious Diseases
-
2.1.2 Oncology
-
2.1.3 Hematology
-
2.1.4 Prenatal Testing
-
2.1.5 Endocrinology
-
2.1.6 Other Applications
-
-
2.2 By Technology
-
2.2.1 PCR
-
2.2.2 Genetic Sequencing
-
2.2.3 Hybridization
-
2.2.4 Microarray
-
-
2.3 By End User
-
2.3.1 Hospitals
-
2.3.2 Homecare
-
2.3.3 Other End Users
-
-
2.4 By Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle-East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle-East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Global Point-of-Care Molecular Diagnostics Market Size FAQs
How big is the Global Point-of-Care Molecular Diagnostics Market?
The Global Point-of-Care Molecular Diagnostics Market size is expected to reach USD 3.67 billion in 2024 and grow at a CAGR of 8.77% to reach USD 5.57 billion by 2029.
What is the current Global Point-of-Care Molecular Diagnostics Market size?
In 2024, the Global Point-of-Care Molecular Diagnostics Market size is expected to reach USD 3.67 billion.